that’s a good point - it’ll be a huge win
2022 - 4 leads with pre-clinical data work-up as per RP11 quality. VP-001, IND approved by FDA, enters clinic - phase 1 - first patient milestone
2023 - OPA1 IND approved, first patient enrolled. RP11 efficacy read outs. Hopefully global headlines. Lead 3/4 IND closer to roadmap. Leads 4-8 hopefully defined with pre-clinical data work up.
2024 - early in the year we’ll need some serious $ injection. Maybe we’ll have enough juicy data by then for our platform, and a licensing $ event by then = we got $ needs covered for future pipeline to clinic
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-31
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.015(8.11%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $419.2K | 2.405M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 326555 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 222720 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |